Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

Figure 2

Time to progression and overall survival according to TIMP-1 status. Kaplan-Meier curve for (A) time to progression (165 events) and (B) overall survival (240 events) for all 264 advanced breast cancer patients treated with gemcitabine plus docetaxel or docetaxel alone (study arms combined) according to TIMP-1 immunohistochemical staining status. Abbreviations: CI = confidence interval; TIMP-1 = tissue inhibitor of metalloproteinases-1.

Back to article page